中文摘要：

目的：探讨乳腺癌患者肿瘤组织中凋亡抑制基因AVENmRNA的表达情况，分析其在临床诊治中的意义。方法：采用SYBR~Green实时荧光定量PCR方法，检测在89例乳腺癌患者癌组织和癌旁组织中的AVENmRNA表达。AVENmRNA的表达与临床病理学和危险因素的关系采用￡检验和单因素方差分析。结果：AVENmRNA的表达在服用避孕药的患者中明显低于未服用避孕药的乳腺癌患者P=O．02，而与肿瘤大小、淋巴结转移、临床分期、ER、PR等临床特征无关P〉O．05，与患者的年龄、BMI指数、怀孕次数、是否绝经、月经初潮年龄、是否母乳喂养、累积行经年数、初产前行经年数等危险因素亦无关P〉0．05。结论：口服避孕药与乳腺癌患者肿瘤AVENmRNA的表达呈负相关。

英文摘要：

Objective： This workaims to investigate the AVEN mRNA level of breast cancer and analyze its clinical significance in the treatment of breast cancer. Methods： SYBR Green real-time quantitative polymerase chain reaction was used to determine AVEN mRNA expression in 89 breast carcinoma and para-carcinoma tissue samples. SPSS 16.0 software was employed for statistical analysis of the data. The relationship ofAVEN mRNA expression with all of the clinicopathologic characteristics and risk factors was evaluated using the t test and ANOVA. The odds ratio values and their confidence intervals were calculated （ 95 % CI ）. P 〈 0.05 was considered statistically significant. Results： The AVEN mRNA level was significantly lower in the breast cancer patients who took con- traceptives than in those who did not （ P = 0.02 ）. The level had no correlation with tumor size, lymph node metastasis, clinical stage, estrogen receptors, progesterone receptors, and other clinical features （ P 〉 0.05 ）. Furthermore, level had no relationship with the pa- tient＇s age, BMI index, number of pregnancies, menopause status, menarche age, and breastfeeding, as well as risk factors such as the number of years of cumulative menstruations and the years of prenatal menstruation before primiparity （ P 〉 0.05 ）. Conclusion： Oral contraceotives are related to the low exoression of aoootosis inhibitor gene AVEN in breast tumor tissue.